Optimizatsiya lecheniya patsientov s akromegaliey: uvelichenie intervala mezhdu in\"ektsiyami pri ispol'zovanii lanreotida
- 作者: Antsiferov M.B1, Pronin V.S1
-
隶属关系:
- 期: 编号 16 (2014)
- 页面: 26-29
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287407
- ID: 287407
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The article discusses various schemes of transfer of patients receiving octreotide, on lanreotide on (Somatulin® Autogel®) in order to optimize therapy by increasing the interval between injections. The results of the last large study in this area, and own author’s data are presented. Increase of the interval between injections of lanreotide while maintaining the therapeutic effect allows to significantly simplify the regimen of injections and improve patients' adherence to therapy.
全文:
参考
- Katznelson L., Atkinson J.L., Cook D.M., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 update: executive summary. Endocr. Pract. 2011 ; 17(4): 636-46.
- Melmed, S., Colao А., Barkan А., et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 2009; 94(5): 1509-17.
- Анциферов М.Б., Пронин В.С., Алексеева Т.М. и др. Настоящее и будущее фармакотерапии акромегалии. Фарматека. 2012; 16: 20-7.
- Andries M., Glintborg D., Kvistborg A., et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l
- Ronchi C.L., Boschetti M., Degli Uberti E.C., et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin. Endocrinol. (Oxf) 2007; 67(4): 512-19.
- Анциферов М.Б., Пронин В.С., Алексеева Т.М. и др. Опыт ведения московского регистра больных акромегалией: возможности решения различных терапевтических задач. Фарматека. 2013; 16: 40-6.
- Инструкция по медицинскому применению лекарственного препарата Соматулин®. ла существенное упрощение режима инъекционной терапии и повышение приверженности пациентов проводимому лечению. Регистрационное удостоверение ЛСР - 003497/09.
- Lelij A., Pronin V., Balcere I., et al. Efficacy and safety of lanreotideautogel (LAN-ATG) 120 mg at extended dosing intervals (EDIs) in acromegalic patients biochemically controlled with octreotide LAR (OCT-LAR) 10 or 20 mg: The LEAD study. Endocrine Abstracts. 2014; 35: 328.
- Schopohl J., Strasburger C.J., Caird D., et al. Efficacy and acceptability of lanreotide Autogel (R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes. 2011; 119(3): 156-62.
补充文件
